Dynamite News Weight loss surgery is more effective in controlling hypertension rates
Bariatric surgery is more effective at controlling hypertension rates, or high blood pressure, in people with obesity and uncontrolled high blood pressure, than blood pressure medication alone. Read further on Dynamite News:
Los Angeles: According to a study published today in the Journal of the American College of Cardiology, bariatric surgery is more effective at controlling hypertension rates, or high blood pressure, in people with obesity and uncontrolled high blood pressure, than blood pressure medication alone.
People who had bariatric surgery had a lower BMI and were on fewer drugs after five years while maintaining normal blood pressure levels than those who solely used antihypertensive medications.
According to the CDC, the U.S. obesity and hypertension rates in adults are 41.9 per cent and 45.4 per cent, respectively.
Read This Also: Odors might prompt certain brain cells to make decisions
Obesity is a proven risk factor for cardiovascular disease and a key contributor to high blood pressure, both of which can increase the chance of a heart attack, stroke, and heart failure.
"In clinical practice, obesity is an overlooked condition.
As a consequence, there is a frequent failure in approaching obesity as a crucial step for mitigating the risk of important cardiovascular risk factors including hypertension," said Carlos Aurelio Schiavon, MD, FACS, lead author of the study and a surgeon specializing in bariatric surgery at Heart Hospital and BP Hospital in Sao Paulo.
Also Read |
Weight loss surgery can be more successful in controlling hypertension rates
Researchers in this study looked at the impact of treating obesity to lower high blood pressure. While there are new medications to treat obesity, long-term adherence to medication can be challenging.
This study looks at bariatric surgery as a better long-term solution to control obesity and, as a result, high blood pressure.
The GATEWAY trial included 100 people (76 per cent of which were female) who had a body mass index (BMI) of around 36.9 kg/m2. All participants had hypertension and were using at least two medications.
Read This Also: Gene therapy may slow progression of a life-threatening cardiac ailment
People with previous cardiovascular events and poorly controlled Type 2 diabetes were excluded.
Subjects were assigned to either Roux-en-Y gastric bypass with medical therapy or medial therapy alone and the primary outcome was reduction of at least 30 per cent antihypertensive medications while maintaining blood pressure levels less than 140/90 mmHg at five years.
At five years, BMI was 28.01 Kg/m2 for those who received bariatric surgery and 36.40 Kg/m2 for those on medical therapy alone. People who had bariatric surgery had an 80.7 per cent reduction in the number of medications they were taking compared to a 13.7 per cent reduction in those only using medical therapy.
Also Read |
New study expands understanding of treatment-resistant hypertension
Hypertension remission, defined as controlled blood pressure without medications, was 46.9 per cent in those who underwent bariatric surgery compared to 2.4 per cent in those on medical therapy alone.
"Our results underscore the importance of approaching obesity in reducing hypertension rates," Schiavon said.
Limitations of the study included that it was a single-centre, open-label study with a small sample size and there was loss of follow-up in some patients.
In an accompanying editorial comment, Michael Hall, MD, MSc, professor and chair of the Department of Medicine at the University of Mississippi Medical Center, said the study provides important long-term data on the benefits of gastric bypass on weight loss and blood pressure control, but questions remain.
"Further studies assessing the threshold for bariatric surgery in people with obesity, optimal timing of bariatric surgery in obese people with cardiometabolic diseases, type of bariatric surgery and comparative studies of obesity pharmacotherapies and bariatric surgery are needed to clarify the optimal treatment pathways for this common and growing disease," he said. (ANI)